Benitec Biopharma effects 1-for-17 reverse stock split to meet Nasdaq minimum bid price

Benitec Biopharma Inc.

Reverse stock split of common stock at 1-for-17 ratio effective July 26, 2023 at 12:01 a.m. ET.
Intended to bring company into compliance with Nasdaq $1.00 minimum bid price requirement for continued listing.
No fractional shares issued; all fractional shares rounded up to nearest whole share.
CUSIP changes to 08205P209; trading symbol BNTC remains unchanged.
Stockholders need not take action; Computershare acts as exchange agent for the split.

item 3.03 item 5.03 item 7.01 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Benitec Biopharma Inc.: Certificate of Amendment to the Amended and Restated Certificate of Incorporation to effect a 1-for-17 reverse stock split (effective 2023-07-26).

Change: charter amendment
Effective: 2023-07-26

Exact text from the filing

On July 25, 2023, Benitec Biopharma Inc. (the “Company”) filed a Certificate of Amendment to the Company’s Amended and Restated Certificate of Incorporation, as amended, with the Secretary of State of the State of Delaware (the “Certificate of Amendment”), which will effect, at 12:01 a.m. Eastern Time, on July 26, 2023 (the “Effective Time”), a 1-for-17 reverse stock split (the “Reverse Stock Split”)

View on SEC.gov

42 governance changes filed in the last 30 days. Browse all governance changes →

Benitec Biopharma Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-193295

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.